Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $3.92 per share. This compares to earnings of $4.01 per share a year ago.
Vertex Pharma misses sales estimates on weak demand for older CF treatments
Vertex Pharmaceuticals missed Wall Street estimates for third-quarter sales on Monday, hurt by weaker-than-expected demand for its older cystic fibrosis (CF) treatments.
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $376.55, representing a +1.95% change from its previous close.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $355.28, denoting a -1.66% change from the preceding trading day.
This Market-Beating Growth Stock Is Set to Outperform Yet Again in 2024
Large-cap growth stocks with wide economic moats and top-shelf management teams have outperformed this year. Vertex Pharmaceuticals, a rare disease specialist, has been one of the strongest perform...
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $367.66, denoting a +1.6% change from the preceding trading day.
Why Vertex (VRTX) is Poised to Beat Earnings Estimates Again
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex Pharmaceuticals (VRTX) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $374, denoting a +0.81% change from the preceding trading day.
The Surprising $5 Billion Opportunity That Drove Vertex Pharmaceuticals Stock To A Record High
Almost three-quarters of prescribed pain meds are opioids, and Vertex could change that. VRTX stock broke out to a record high Thursday.
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $355.20, indicating a -1.5% shift from the previous trading day.
Vertex (VRTX) Gets Positive CHMP Opinion for Kaftrio Expanded Use
Vertex's (VRTX) Kaftrio gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use to treat younger age groups of two to five years...
1 Top Pharma Growth Stock to Buy Today and Hold Forever
Vertex Pharmaceuticals has many avenues for chasing growth both big and small. Its cystic fibrosis medicines continue to remain a rock-solid base of revenue.
Vertex Pharmaceuticals Still Looks Attractive
Vertex Pharmaceuticals' Q2 financials showed strong revenue growth. The company's core portfolio of drugs for cystic fibrosis treatment has additional market opportunities. Also, Vertex has some un...
Could Vertex Pharmaceuticals Stock Help You Become a Millionaire?
Vertex Pharmaceuticals is a leader in cystic fibrosis treatments. The company is working on expanding its business, which will open up more growth opportunities.
Related Companies